Completed PHASE1 INTERVENTIONAL 4-arm NCT00754871

Pharmacodynamic Characterization of Dienogest

A Double-blind, Randomized, Dose-controlled Study to Evaluate Pharmacodynamic Properties of Four Oral Doses of Dienogest (DNG) in 100 Healthy Young Female Volunteers Over a Period of Two Cycles up to a Maximum of 72 Days

Sponsor: Bayer

Conditions Pharmacodynamics

Interventions Dienogest (81150037) Dienogest (81150231) Dienogest (81150746) Dienogest (SH T00660A)

Updated 5 times since 2017 Last updated: Jan 26, 2015 Started: Sep 30, 2008 Primary completion: Jul 31, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00754871, this PHASE1 trial focuses on Pharmacodynamics and remains completed. Sponsored by Bayer, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands